Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pool...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Thirunavukkarasu, Krishan, DeMasi, Ryan, Geier, Jamie, Kwok, Kenneth, Wang, Lisy, Riese, Richard, Wollenhaupt, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530353/
https://www.ncbi.nlm.nih.gov/pubmed/28143815
http://dx.doi.org/10.1136/annrheumdis-2016-210457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530353/
https://www.ncbi.nlm.nih.gov/pubmed/28143815
http://dx.doi.org/10.1136/annrheumdis-2016-210457

Ejemplares similares